Erythropoiesis‐stimulating agents and incident malignancy in chronic kidney and end‐stage renal disease: A population‐based study

Research investigating incident malignancy risk in erythropoiesis‐stimulating agent (ESA) users with chronic kidney disease (CKD) is lacking. We aimed to compare the incident cancer risk between ESA and non‐ESA users with CKD or end‐stage renal disease (ESRD). In this retrospective cohort study, all...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yu‐Shan, Li, Ming‐Feng, Lin, Mei‐Chen, Ou, Shih‐Hsiang, Wang, Jen‐Hung, Huang, Chien‐Wei, Chou, Kang‐Ju, Fang, Hua‐Chang, Lee, Po‐Tsang, Hsu, Chih‐Yang, Chen, Jin‐Shuen, Chen, Hsin‐Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468572/
https://www.ncbi.nlm.nih.gov/pubmed/35699124
http://dx.doi.org/10.1111/cts.13353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9468572/
https://www.ncbi.nlm.nih.gov/pubmed/35699124
http://dx.doi.org/10.1111/cts.13353

Ejemplares similares